Further experiments will be developed with complementary ovarian carcinoma cell lines overexpressing HER-2 receptor to decipher the role of RhoB/PTEN cross-talk and/or expression vs the HER-2 expression level to increase our knowledge in ovarian carcinomas treatment. This evidence concerns the gene ERBB2 and ovarian carcinoma.